Novo Nordisk, Evotec
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much ...
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...
For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback